Order Tests Now

Earlier Cancer Detection.

Reliable Results.

Proactive screening to keep living your best life with earlier multi-cancer detection.*

ORDER NOW

The EPISEEK™ Test detects the most common cancers before symptoms appear.

EPISEEK™ is a cutting-edge multi-cancer detection (MCD) test that uses a simple blood draw to identify DNA changes linked to over 60 types of cancer. By detecting hypermethylated DNA loci—i.e., regions consistently altered across multiple cancer types—EPISEEK™ provides reliable, early detection, even before symptoms appear.

LEARN MORE

*The EPISEEK™ test may not identify signals for every type of cancer at every stage. There is a possibility of false positive and false negative results.

A

Adrenal Cortical Carcinoma

Ampulla of Vater

Anus

Appendix, Carcinoma

B

Bile Ducts, Distal

Bile Ducts, Intrahepatic

Bile Ducts, Perihilar

Bladder, Urinary

Bone

Brain

Breast

C

Cervix

Colon and Rectum

E

Esophagus and Esophagogastric Junction

G

Gallbladder

Gastrointestinal Stromal Tumor

Gestational Trophoblastic Neoplasms

K

Kidney

L

Larynx

Leukemia

Liver

Lung

Lymphoma (Hodgkin and Non-Hodgkin)

M

Melanoma of the Skin

Merkel Cell Carcinoma

Mesothelioma, Malignant Pleural

N

Nasal Cavity and Paranasal Sinuses

Nasopharynx

Neuroendocrine Tumors of the Appendix

Neuroendocrine Tumors of the Colon and Rectum

Neuroendocrine Tumors of the Pancreas

O

Oral Cavity

Oropharynx (HPV-Mediated, p16+)

Oropharynx (p16-) and Hypopharynx

Ovary, Fallopian Tube and Primary Peritoneum

P

Pancreas, exocrine

Penis

Plasma Cell Myeloma and Plasma Cell Disorders

Prostate

S

Small Intestine

Soft Tissue Sarcoma of the Abdomen and Thoracic Visceral Organs

Soft Tissue Sarcoma of the Head and Neck

Soft Tissue Sarcoma of the Retroperitoneum

Soft Tissue Sarcoma of the Trunk and Extremities

Soft Tissue Sarcoma Unusual Histologies and Sites

Stomach

T

Testis

U

Ureter, Renal Pelvis

Uterus, Carcinoma and Carcinosarcoma

Uterus, Sarcoma

V

Vagina

Vulva

A

Adrenal Cortical Carcinoma

Ampulla of Vater

Anus

Appendix, Carcinoma

B

Bile Ducts, Distal

Bile Ducts, Intrahepatic

Bile Ducts, Perihilar

Bladder, Urinary

Bone

Brain

Breast

C

Cervix

Colon and Rectum

E

Esophagus and Esophagogastric Junction

G

Gallbladder

Gastrointestinal Stromal Tumor

Gestational Trophoblastic Neoplasms

K

Kidney

L

Larynx

Leukemia

Liver

Lung

Lymphoma (Hodgkin and Non-Hodgkin)

M

Melanoma of the Skin

Merkel Cell Carcinoma

Mesothelioma, Malignant Pleural

N

Nasal Cavity and Paranasal Sinuses

Nasopharynx

Neuroendocrine Tumors of the Appendix

Neuroendocrine Tumors of the Colon and Rectum

Neuroendocrine Tumors of the Pancreas

O

Oral Cavity

Oropharynx (HPV-Mediated, p16+)

Oropharynx (p16-) and Hypopharynx

Ovary, Fallopian Tube and Primary Peritoneum

P

Pancreas, exocrine

Penis

Plasma Cell Myeloma and Plasma Cell Disorders

Prostate

S

Small Intestine

Soft Tissue Sarcoma of the Abdomen and Thoracic Visceral Organs

Soft Tissue Sarcoma of the Head and Neck

Soft Tissue Sarcoma of the Retroperitoneum

Soft Tissue Sarcoma of the Trunk and Extremities

Soft Tissue Sarcoma Unusual Histologies and Sites

Stomach

T

Testis

U

Ureter, Renal Pelvis

Uterus, Carcinoma and Carcinosarcoma

Uterus, Sarcoma

V

Vagina

Vulva

How It Works

EPISEEK™ redefines cancer detection and monitoring, identifying cancer with more specificity than imaging and by being more accessible than invasive tissue biopsies.

Provider Draws Blood

Test Is Sent to Lab

Specimen Is Analyzed

Provider Explains Results

Results in Just 7–10 Days

LEARN MORE

Who Is EPISEEK™ For?

The EPISEEK™ test is recommended for the following :

R

Individuals at Higher Risk

  • Those with a personal or family history of cancer
  • Individuals with lifestyle or environmental exposures that increase risk (e.g., firefighters)
R

Health-Conscious Individuals

  • People who prioritize preventive health care and want to take proactive steps to monitor their health
R

Employers or Wellness Programs

  • Organizations aiming to enhance employee health benefits by providing access to advanced health screenings
R

Individuals Aged 45 or Older

R

Healthcare Providers

  • Physicians, oncologists, and general practitioners seeking advanced diagnostic tools to offer their patients
  • Clinics and hospitals that want to integrate cutting-edge cancer screening into their services
R

Researchers and Institutions

  • Institutions interested in leveraging innovation technologies for further studies in early cancer detection

The EPISEEK™ test is not recommended for the following:

Individuals who are pregnant

Individuals undergoing active cancer treatment or those with an active known malignancy

Individuals aged 21 years or younger

Talk to your healthcare provider about including the EPISEEK™ test as part of your annual checkup!

LEARN MORE

The Right Provider Is Committed to Keeping You Healthy

“As a physician, I know that early detection is critical in the fight against cancer. The EPISEEK™ liquid biopsy test is a groundbreaking tool that identifies cancer at its earliest stages, when it’s most treatable. I highly recommend Precision Epigenomics for its accuracy and its potential to save lives by catching cancer before symptoms begin. Not only do I order EPISEEK™ for my patients, but my healthcare provider also ordered it for me.”

— Kristine Romine, MD

“I use EPISEEK™ alongside standard guideline-based cancer screenings for my patients. It offers exceptional specificity and is an excellent tool for early detection. EPISEEK™ screens for the top 10 leading causes of cancer-related deaths, including brain cancer, and is available at a more accessible price point than alternatives. It’s a great choice for my patients to help with early detection of cancer.”

— Carl Seger, MD

“When I received my EPISEEK™ results showing no cancer signals, it felt like a weight had been lifted. Adding this test to my regular screenings gives me confidence that I’m doing everything I can to protect my health. That peace of mind is priceless. I encourage anyone thinking about additional screening to take that step—you won’t regret it.”

— Lissa Druss

Recent Articles